Beneficial effects of probiotics, prebiotics, synbiotics, and psychobiotics in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 21, Issue 7, 2015, Pages 1674-1682

  Wasilewski, Andrzej ^a   Zielińska, Marta ^a   Storr, Martin ^b   Fichna, Jakub ^a,c  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF MUNICH   (Germany)

^c MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Crohn's disease; intestinal microbiota; prebiotics; probiotics; ulcerative colitis

Indexed keywords

MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; PREBIOTIC AGENT; PROBIOTIC AGENT; PSYCHOBIOTIC AGENT; PSYCHOTROPIC AGENT; SYNBIOTIC AGENT; UNCLASSIFIED DRUG;

BACTEROIDES; CITROBACTER RODENTIUM; CLOSTRIDIUM PERFRINGENS; CROHN DISEASE; CYTOKINE PRODUCTION; FATTY ACID METABOLISM; GENETIC VARIABILITY; HUMAN; INTESTINE FLORA; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS DELBRUECKII SUBSP. BULGARICUS; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; LACTOBACILLUS RHAMNOSUS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM KANSASII; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; REVIEW; STREPTOCOCCUS EQUINUS; STREPTOCOCCUS SALIVARIUS; STREPTOCOCCUS THERMOPHILUS; TREATMENT RESPONSE; ULCERATIVE COLITIS; INFLAMMATORY BOWEL DISEASES; INTESTINE MUCOSA; MICROBIOLOGY; MICROFLORA;

HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MICROBIOTA; PREBIOTICS; PROBIOTICS; REMISSION INDUCTION; SYNBIOTICS;

EID: 84932098334     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000364     Document Type: Review

References (104)

1. Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol. 1977;31:107-133.
2. Backhed F, Ley RE, Sonnenburg JL, et al. Host-bacterial mutualism in the human intestine. Science. 2005;307:1915-1920.
3. de Moreno de LA, Dogi CA, Galdeano CM, et al. Effect of the administration of a fermented milk containing Lactobacillus casei DN-114001 on intestinal microbiota and gut associated immune cells of nursing mice and after weaning until immune maturity. BMC Immunol. 2008;9:27.
4. Hooper LV, Wong MH, Thelin A, et al. Molecular analysis of commensal host-microbial relationships in the intestine. Science. 2001;291:881-884.
5. Hattori M, Taylor TD. The human intestinal microbiome: a new frontier of human biology. DNA Res. 2009;16:1-12.
6. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124:837-848.
7. Tuomola EM, Salminen SJ. Adhesion of some probiotic and dairy Lactobacillus strains to Caco-2 cell cultures. Int J Food Microbiol. 1998;41: 45-51.
8. OToole PW, Cooney JC. Probiotic bacteria influence the composition and function of the intestinal microbiota. Interdiscip Perspect Infect Dis. 2008;2008:175285.
9. Cryan JF, Dinan TG. Mind-Altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012;13:701-712.
10. Shanahan F. Crohn's disease. Lancet. 2002;359:62-69.
11. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucinerich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411:599-603.
12. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology. 2004;126:1620-1633.
13. Chandran P, Satthaporn S, Robins A, et al. Inflammatory bowel disease: dysfunction of GALT and gut bacterial flora (II). Surgeon. 2003;1:125-136.
14. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998;66:5224-5231.
15. Scribano ML, Prantera C. Antibiotics and inflammatory bowel diseases. Dig Dis. 2013;31:379-384.
16. DHaens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114:262-267.
17. Greenstein RJ. Is Crohn's disease caused by a mycobacterium?. Comparisons with leprosy, tuberculosis, and Johne's disease. Lancet Infect Dis. 2003;3:507-514.
18. Romero C, Hamdi A, Valentine JF, et al. Evaluation of surgical tissue from patients with Crohn's disease for the presence of Mycobacterium avium subspecies paratuberculosis DNA by in situ hybridization and nested polymerase chain reaction. Inflamm Bowel Dis. 2005;11:116-125.
19. Chiodini RJ. Crohn's disease and the mycobacterioses: a review and comparison of two disease entities. Clin Microbiol Rev. 1989;2:90-117.
20. Lakatos PL, Fischer S, Lakatos L, et al. Current concept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take toll?. World J Gastroenterol. 2006; 12:1829-1841.
21. Hinoda Y, Akashi H, Suwa T, et al. Immunohistochemical detection of MUC2 mucin core protein in ulcerative colitis. J Clin Lab Anal. 1998;12: 150-153.
22. Buisine MP, Desreumaux P, Leteurtre E, et al. Mucin gene expression in intestinal epithelial cells in Crohn's disease. Gut. 2001;49:544-551.
23. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009; 361:2066-2078.
24. Liu Y, van Kruiningen HJ, West AB, et al. Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology. 1995;108:1396-1404.
25. Dixon B. Secrets of the Bulgarian bacillus. Lancet Infect Dis. 2002; 2:260.
26. Baharav E, Mor F, Halpern M, et al. Lactobacillus GG bacteria ameliorate arthritis in Lewis rats. J Nutr. 2004;134:1964-1969.
27. Demirer S, Aydintug S, Aslim B, et al. Effects of probiotics on radiationinduced intestinal injury in rats. Nutrition. 2006;22:179-186.
28. Kamil R, Geier MS, Butler RN, et al. Lactobacillus rhamnosus GG exacerbates intestinal ulceration in a model of indomethacin-induced enteropathy. Dig Dis Sci. 2007;52:1247-1252.
29. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoeapredominant irritable bowel syndrome. Aliment Pharmacol Ther. 2003; 17:895-904.
30. Tooley KL, Howarth GS, Lymn KA, et al. Oral ingestion of streptococcus thermophilus diminishes severity of small intestinal mucositis in methotrexate treated rats. Cancer Biol Ther. 2006;5:593-600.
31. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:305-309.
32. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999;354:635-639.
33. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005;100:1539-1546.
34. Schultz M, Timmer A, Herfarth HH, et al. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol. 2004;4:5.
35. Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut. 2002;51: 405-409.
36. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122:44-54.
37. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617-1623.
38. Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci. 2000;45: 1462-1464.
39. Prantera C, Scribano ML. Probiotics and Crohn's disease. Dig Liver Dis. 2002;34(suppl 2):S66-S67.
40. Bousvaros A, Guandalini S, Baldassano RN, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis. 2005;11:833-839.
41. Marteau P, Lemann M, Seksik P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut. 2006;55:842-847.
42. Van GA, Dewit O, Louis E, et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflamm Bowel Dis. 2007;13:135-142.
43. Cui HH, Chen CL, Wang JD, et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol. 2004; 10:1521-1525.
44. Ishikawa H, Akedo I, Umesaki Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr. 2003;22:56-63.
45. Zocco MA, dal Verme LZ, Cremonini F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:1567-1574.
46. Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut. 2005;54:242-249.
47. Shadnoush M, Shaker HR, Mehrabi Y, et al. Probiotic yogurt affects proand anti-inflammatory factors in patients with inflammatory bowel disease. Iran J Pharm Res. 2013;12:929-936.
48. Lammers KM, Brigidi P, Vitali B, et al. Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunol Med Microbiol. 2003;38:165-172.
49. Mennigen R, Nolte K, Rijcken E, et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol. 2009;296:G1140-G1149.
50. Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104:437-443.
51. Shen J, Zuo ZX, Mao AP. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-Analysis of randomized controlled trials. Inflamm Bowel Dis. 2014; 20:21-35.
52. Dieleman L, Hoentjen F. Probiotics have a limited role in the treatment of inflammatory bowel disease [in Dutch]. Ned Tijdschr Geneeskd. 2012; 156:A5206.
53. Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014;8:1179-1207.
54. Kuhbacher T, Ott SJ, Helwig U, et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut. 2006;55:833-841.
55. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125: 1401-1412.
56. Cummings JH, Macfarlane GT. Gastrointestinal effects of prebiotics. Br J Nutr. 2002;87(suppl 2):S145-S151.
57. Roberfroid MB, Delzenne NM. Dietary fructans. Annu Rev Nutr. 1998; 18:117-143.
58. Videla S, Vilaseca J, Antolin M, et al. Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat. Am J Gastroenterol. 2001;96:1486-1493.
59. Holma R, Juvonen P, Asmawi MZ, et al. Galacto-oligosaccharides stimulate the growth of bifidobacteria but fail to attenuate inflammation in experimental colitis in rats. Scand J Gastroenterol. 2002;37:1042-1047.
60. Moreau NM, Martin LJ, Toquet CS, et al. Restoration of the integrity of rat caeco-colonic mucosa by resistant starch, but not by fructooligosaccharides, in dextran sulfate sodium-induced experimental colitis. Br J Nutr. 2003;90:75-85.
61. Hoentjen F, Welling GW, Harmsen HJ, et al. Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microflora changes and immunomodulation. Inflamm Bowel Dis. 2005;11:977-985.
62. Koleva PT, Valcheva RS, Sun X, et al. Inulin and fructooligosaccharides have divergent effects on colitis and commensal microbiota in HLA-B27 transgenic rats. Br J Nutr. 2012;108:1633-1643.
63. Lara-Villoslada F, Debras E, Nieto A, et al. Oligosaccharides isolated from goat milk reduce intestinal inflammation in a rat model of dextran sodium sulfate-induced colitis. Clin Nutr. 2006;25:477-488.
64. Rumi G, Tsubouchi R, Okayama M, et al. Protective effect of lactulose on dextran sulfate sodium-induced colonic inflammation in rats. Dig Dis Sci. 2004;49:1466-1472.
65. Lindsay JO, Whelan K, Stagg AJ, et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut. 2006;55:348-355.
66. Benjamin JL, Hedin CR, Koutsoumpas A, et al. Randomised, doubleblind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut. 2011;60:923-929.
67. Hafer A, Kramer S, Duncker S, et al. Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study. BMC Gastroenterol. 2007;7:36.
68. Casellas F, Borruel N, Torrejon A, et al. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. Aliment Pharmacol Ther. 2007;25:1061-1067.
69. Gibson GR, Beatty ER, Wang X, et al. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology. 1995;108:975-982.
70. Muccioli GG, Naslain D, Backhed F, et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol. 2010;6:392.
71. Looijer-van Langen MA, Dieleman LA. Prebiotics in chronic intestinal inflammation. Inflamm Bowel Dis. 2009;15:454-462.
72. Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341:569-573.
73. Bengmark S. Bioecologic control of the gastrointestinal tract: the role of flora and supplemented probiotics and synbiotics. Gastroenterol Clin North Am. 2005;34:413-436, viii.
74. Bengmark S, Martindale R. Prebiotics and synbiotics in clinical medicine. Nutr Clin Pract. 2005;20:244-261.
75. Arai S, Morinaga Y, Yoshikawa T, et al. Recent trends in functional food science and the industry in Japan. Biosci Biotechnol Biochem. 2002;66: 2017-2029.
76. Ooi LG, Ahmad R, Yuen KH, et al. Lactobacillus gasseri [corrected] CHO-220 and inulin reduced plasma total cholesterol and low-density lipoprotein cholesterol via alteration of lipid transporters. J Dairy Sci. 2010;93:5048-5058.
77. Malaguarnera G, Giordano M, Nunnari G, et al. Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives. World J Gastroenterol. 2014;20:16639-16648.
78. Rodrigues FC, Castro AS, Rodrigues VC, et al. Yacon flour and Bifidobacterium longum modulate bone health in rats. J Med Food. 2012;15:664-670.
79. Bomba A, Nemcova R, Gancarcikova S, et al. Improvement of the probiotic effect of micro-organisms by their combination with maltodextrins, fructo-oligosaccharides and polyunsaturated fatty acids. Br J Nutr. 2002;88(suppl 1):S95-S99.
80. Steed H, Macfarlane GT, Blackett KL, et al. Clinical trial: the microbiological and immunological effects of synbiotic consumption-A randomized double-blind placebo-controlled study in active Crohn's disease. Aliment Pharmacol Ther. 2010;32:872-883.
81. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464:59-65.
82. Fichna J, Storr MA. Brain-gut interactions in IBS. Front Pharmacol. 2012;3:127.
83. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol. 2009;6:306-314.
84. Gareau MG, Jury J, MacQueen G, et al. Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation. Gut. 2007;56:1522-1528.
85. Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol. 2012;10:735-742.
86. Irwin MR, Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun. 2007;21:374-383.
87. Pavlov VA, Tracey KJ. Neural regulators of innate immune responses and inflammation. Cell Mol Life Sci. 2004;61:2322-2331.
88. Iyer LM, Aravind L, Coon SL, et al. Evolution of cell-cell signaling in animals: did late horizontal gene transfer from bacteria have a role?. Trends Genet. 2004;20:292-299.
89. Bravo JA, Forsythe P, Chew MV, et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A. 2011;108: 16050-16055.
90. Bercik P, Denou E, Collins J, et al. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology. 2011;141:599-609.
91. Duman RS. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med. 2004;5:11-25.
92. Wall R, Marques TM, O'sullivan O, et al. Contrasting effects of Bifidobacterium breve NCIMB 702258 and Bifidobacterium breve DPC 6330 on the composition of murine brain fatty acids and gut microbiota. Am J Clin Nutr. 2012;95:1278-1287.
93. Innis SM. Dietary (n-3) fatty acids and brain development. J Nutr. 2007; 137:855-859.
94. Maekawa M, Takashima N, Matsumata M, et al. Arachidonic acid drives postnatal neurogenesis and elicits a beneficial effect on prepulse inhibition, a biological trait of psychiatric illnesses. PLoS One. 2009;4:e5085.
95. Forsythe P, Bienenstock J. Immunomodulation by commensal and probiotic bacteria. Immunol Invest. 2010;39:429-448.
96. Duerkop BA, Vaishnava S, Hooper LV. Immune responses to the microbiota at the intestinal mucosal surface. Immunity. 2009;31:368-376.
97. Desbonnet L, Garrett L, Clarke G, et al. The probiotic Bifidobacteria infantis: an assessment of potential antidepressant properties in the rat. J Psychiatr Res. 2008;43:164-174.
98. Wichers MC, Maes M. The role of indoleamine 2, 3-dioxygenase (IDO) in the pathophysiology of interferon-Alpha-induced depression. J Psychiatry Neurosci. 2004;29:11-17.
99. Maes M, Leonard BE, Myint AM, et al. The new 5-HT hypothesis of depression: cell-mediated immune activation induces indoleamine 2, 3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:702-721.
100. Myint AM, Kim YK, Verkerk R, et al. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord. 2007; 98:143-151.
101. Salaga M, Sobczak M, Fichna J. Inhibition of proteases as a novel therapeutic strategy in the treatment of metabolic, inflammatory and functional diseases of the gastrointestinal tract. Drug Discov Today. 2013;18: 708-715.
102. Salaga M, Mokrowiecka A, Zakrzewski PK, et al. Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH). J Crohns Colitis. 2014;8:998-1009.
103. Fichna J, Salaga M, Stuart J, et al. Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides. Neurogastroenterol Motil. 2014;26:470-481.
104. Rousseaux C, Thuru X, Gelot A, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007;13:35-37.